Novartis has agreed to purchase the remaining 23% of their share in Alcon for $168 per share.
Finnish researchers report on registry data and changing workload resulting from anti-VEGF therapies
The number of patients with retinal vascular diseases is expected to increase over time due to the aging population and lifestyle changes
Higher Molar Dose and Its Translation into Clinical Practice
European Medicines Agency will assess semaglutide for link to NAION
The Danish Medicines Agency requested the EMA's Pharmacovigilance Risk Assessment Committee review reports on the vision-threatening condition
Shining new light on ocular surface care
Low-level light therapy for dry eye disease and chalazion
A history of the femtosecond laser in the United States and Europe
The timeline demonstrates international innovation and collaboration
Balancing the promises and challenges of artificial intelligence
Sophisticated programmes require an evolving mindset